Clinical response of patients with relapsed/refractory MM receiving VMPT
| . | All patients, no. (%) . | VMPT as second-line therapy, no. (%) . | VMPT as third-line therapy, no. (% . |
|---|---|---|---|
| No. of patients | 30 | 14 | 16 |
| CR or VGPR: greater than 90% myeloma protein reduction | 13 (43) | 8 (57) | 5 (31) |
| CR: immunofixation-negative | 5 (17) | 5 (36) | 0 (0) |
| VGPR: 90%-99% myeloma protein reduction | 8 (27) | 3 (21) | 5 (31) |
| PR: 50%-89% myeloma protein reduction | 7 (23) | 3 (21) | 4 (25) |
| SD | 8 (27) | 3 (21) | 5 (31) |
| Progressive disease | 2 (7) | 0 (0) | 2 (13) |
| . | All patients, no. (%) . | VMPT as second-line therapy, no. (%) . | VMPT as third-line therapy, no. (% . |
|---|---|---|---|
| No. of patients | 30 | 14 | 16 |
| CR or VGPR: greater than 90% myeloma protein reduction | 13 (43) | 8 (57) | 5 (31) |
| CR: immunofixation-negative | 5 (17) | 5 (36) | 0 (0) |
| VGPR: 90%-99% myeloma protein reduction | 8 (27) | 3 (21) | 5 (31) |
| PR: 50%-89% myeloma protein reduction | 7 (23) | 3 (21) | 4 (25) |
| SD | 8 (27) | 3 (21) | 5 (31) |
| Progressive disease | 2 (7) | 0 (0) | 2 (13) |